In previous work we observed that cytotoxic tTK expressing hAMSCs that targeted the GSC niche differentiated to vascular components in close proximity to CD133 expressing GBM cells and were capable of reducing tumor burden by a factor or 104 in the presence of GCV. Here, TTK is linked to glioblastoma.